HealthcareServices

Bleeding Disorder Testing Global Forecast: Market to Scale Up to $23.53 Billion by 2030 at 7.8% CAGR

February 20, 2026February 20, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the bleeding disorder testing market from 2026–2035 with trusted insights from The Business Research Company

How much is the Bleeding Disorder Testing Market valued at in 2026, and what valuation is forecast for 2030?

The bleeding disorder testing market has shown significant expansion in recent years. It is anticipated to increase from $16.18 billion in 2025 to $17.46 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.9%. The market’s historical growth is largely due to the increasing prevalence of inherited bleeding disorders, wider adoption of laboratory diagnostics, availability of coagulation analyzers, growth of hospital diagnostic services, and rising clinical awareness of bleeding disorders.

The bleeding disorder testing market is projected to experience substantial expansion in the coming years. Its valuation is anticipated to reach $23.54 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.8%. This growth during the projection period stems from factors such as heightened demand for swift diagnostic methods, the broadening of personalized medicine strategies, increasing capital allocation towards diagnostic automation, greater uptake of point-of-care testing, and the incorporation of AI-powered diagnostic analytics. Key trends identified for the upcoming period encompass improvements in the precision of coagulation testing, wider deployment of point-of-care diagnostic tools, increased use of automated blood analyzers, the expansion of genetic testing specifically for bleeding disorders, and improved integration of digital laboratory systems.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18263&type=smp

What Drivers Are Influencing The Growth Of The Bleeding Disorder Testing Market?

A growing volume of clinical trials is anticipated to drive expansion in the bleeding disorder testing market in the future. These trials constitute research investigations evaluating the safety and effectiveness of new medical treatments, therapies, drugs, or technologies for human use. This surge in clinical trials stems from progress in medical research, increased funding for healthcare innovation, and a heightened need for novel treatments and therapies. Within clinical trials, bleeding disorder testing serves to appraise the effectiveness and safety of emerging medications and therapies for bleeding disorders, determine their ability to manage or rectify clotting issues, and track patient reactions to guarantee appropriate dosing and maximum effectiveness. As an illustration, data from ClinicalTrials.gov, a US-based clinical trial registry, indicates approximately 477,228 clinical trials had been registered by the close of 2023, representing an increase from 437,507 in 2022. Consequently, the expanding quantity of clinical trials is fueling the growth of the bleeding disorder testing market.

How Is The Bleeding Disorder Testing Market Organized Into Various Segments?

The bleeding disorder testing market covered in this report is segmented –

1) By Product Type: Reagents And Consumables, Instruments

2) By Indication: Hemophilia A, Hemophilia B, Von Willebrand Disease, Idiopathic Thrombocytopenic Purpura, Other Indications

3) By End User: Hospitals And Clinics, Diagnostic Centers, Other End Users

Subsegments:

1) By Reagents And Consumables: Coagulation Reagents, Plasma And Blood Collection Consumables, Hemostasis Reagents, Factor Deficiency Assay Kits, Activated Partial Thromboplastin Time (APTT) Reagents

2) By Instruments: Coagulation Analyzers, Platelet Function Analyzers, Hemostasis Testing Instruments, Point-Of-Care Testing Devices, Automated Blood Testing Systems

Which Trends Are Guiding The Evolution Of The Bleeding Disorder Testing Market?

Leading companies in the bleeding disorder testing market are concentrating on creating innovative products, such as gene therapy for Hemophilia B, to deliver enduring solutions, remedy genetic bleeding disorders, improve treatment results, and broaden their market presence. Hemophilia B, a form of bleeding disorder, is characterized by an insufficient amount of clotting factor IX, which is vital for proper blood clotting. Gene therapy for Hemophilia B represents an innovative treatment designed to offer a lasting solution by targeting the fundamental genetic flaw causing the condition. For instance, in February 2023, CSL Limited, an Australian biotechnology firm, and the European Commission granted conditional marketing authorization (CMA) for HEMGENIX, which is recognized as the inaugural and sole single-dose gene therapy for treating severe and moderately severe hemophilia B. This one-time intervention seeks to provide sustained effectiveness, thereby diminishing or eradicating the necessity for ongoing factor replacement therapy. HEMGENIX is notable for its groundbreaking gene therapy approach, offering a transformative alternative for patients with hemophilia B and potentially altering the current standard of care in the field.

Who Are The Primary Competitors In The Global Bleeding Disorder Testing Market?

Major companies operating in the bleeding disorder testing market are Siemens Healthineers AG, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Sysmex Corporation, Diagnostica Stago, Werfen Group, Sekisui Chemical Co. Ltd., Helena Laboratories, HORIBA Ltd., Mindray Medical International Limited, Nihon Kohden Corporation, Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Randox Laboratories Ltd., Haemonetics Corporation, QuidelOrtho Corporation, Instrumentation Laboratory, Beckman Coulter Inc., Grifols S.A., Meridian Bioscience Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/bleeding-disorder-testing-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Bleeding Disorder Testing Market?

North America was the largest region in the bleeding disorder testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bleeding disorder testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Bleeding Disorder Testing Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=18263&type=smp

Browse Through More Reports Similar to the Global Bleeding Disorder Testing Market 2026, By The Business Research Company

Clinical Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-diagnostics-global-market-report

Bleeding Disorders Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/bleeding-disorders-treatment-global-market-report

Blood Screening Market Report 2026

https://www.thebusinessresearchcompany.com/report/blood-screening-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795